H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Summit Therapeutics to $45 from $30 and keeps a Buy rating on the shares. The firm says the ivonescimab data in head and neck squamous cell carcinoma and colorectal cancer showcase expanded opportunities beyond lung cancer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT: